Dept. of Research & Development [email protected] 540-985-8510 Clinical Trial Website Request The Principal Investigator or his/her designee is responsible for completing this form when a new clinical trial needs to be added to the external website: http://www.carilionclinic.org/research/clinical-trials-virginia. Be sure to use lay language and avoid too much detail. All sections are required so any incomplete forms will be returned. The Dept. of Research & Development and Strategic Development retain the right to edit or modify any information that is submitted for publication. Please email form to R&D ([email protected]) and allow 5 business days for the information to post to the website. Information A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions. Project Title (full) Project Title (abbreviated – limit 100 characters Principal Investigator Contact to be listed The ABSORB trial Gary Swank MD Name: Telephone IRB Approved? Yes No Department R & D Vivian Wilson RN 540-632-9852 Clinical Research Nurse/Coordinator Email [email protected] Title Division Interventional Cariology Description Protocol Description (limit 200 words) Eligibility Criteria The trial is called ABSORB IV Randomized Controlled Trial, which is a clinical evaluation of Absorb™ Bioresorbable Vascular Scaffold (BVS) in the treatment of subjects with de novo native coronary artery lesions. ABSORB IV is currently enrolling subjects who have evidence of myocardial ischemia suitable for PCI. The primary objective of this study is to assess the safety and effectiveness of the Absorb BVS compared with the XIENCE family stent systems (XIENCE Alpine, XIENCE V, XIENCE PRIME, and XIENCE Xpedition) for the treatment of patients with ischemic heart disease. ABSORB IV is a prospective, randomized (1:1 Absorb BVS to XIENCE), single-blind, multi-center trial, registering approximately 3,000 subjects. Adult patients with documented coronary artery disease that have 1-3 native coronary artery lesions (blockages) that meet the angiographic criteria for the trial. Publish Dates Date to start displaying content Date to archive content Immediately N/A Additional Information Would you like to add directions to your office? Yes No If yes, provide directions below: 1/2 Version date 3/2013 Extramural Proposals Dept. of Research & Development [email protected] Would you like to add a photo to this page? Yes No If yes, provide photo when submitting or link below: Is there a link, like clinicaltrials.gov, that you would like to add? Yes https://clinicaltrials.gov/ct2/show/NCT02173379?term=absorb&rank=10 No If yes, provide the link below: Version date 3/2013 2/2
© Copyright 2026 Paperzz